Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080319 | 0.88 | ACHE (0.47) | POLBACHEKDM4ETDP1ABL1 | |
| SCHEMBL13765410 | 0.86 | ACHE (0.52) | POLBACHEKMT2AKDM4ETDP1 | |
| SCHEMBL4084307 | 0.84 | ACHE (0.57) | POLBACHEAPEX1KMT2AATM | |
| SCHEMBL15447057 | 0.82 | POLB (0.47) | POLBAPEX1KMT2AATMKDM4E | |
| SCHEMBL4090675 | 0.81 | ALDH1A1 (0.57) | POLBKDM4ETDP1ALDH1A1MAPT | |
| SCHEMBL4085152 | 0.81 | KMT2A (0.49) | POLBKMT2AATMKDM4EL3MBTL1 | |
| SCHEMBL4084211 | 0.81 | ACHE (0.57) | POLBACHEKDM4ETDP1ABL1 | |
| SCHEMBL28502518 | 0.81 | ACHE (0.57) | POLBACHEKMT2AABL1RIN1 | |
| SCHEMBL4083743 | 0.81 | ELANE (0.55) | POLBACHEKDM4ETDP1ABL1 | |
| SCHEMBL18130855 | 0.80 | ACHE (0.55) | POLBACHEKMT2AKDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | claimed |
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | disclosed |
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| WO-2009092176-A2 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186138-A1 | Method of Flavoring | TAS2R5, TAS2R50, TAS2R10 | POLB 2130/4885ACHE 3270/4885APEX1 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.